Co-Enzyme Q10
ApprovedSmall molecule
Co-Enzyme Q10 is one of 86 small molecule programs targeting Ovarian Reserve. It is currently in Approved.
3
Indications
3
Total Trials
2
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Co-Enzyme Q10
TTanta University
Approved
Aranesp
AmgenPreclinical
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Reserve1 trial
of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve
Not yet recruiting·—·Phase 3·NCT06405204·200 enrolled
Sepsis1 trial
Effect of Montelukast Versus Co Enzyme in Sepsis
Completed·—·Phase 2/3·NCT05293132·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Co-Enzyme Q10. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTanta University